Artwork for podcast The Stock Power Podcast
Don’t Count on Biogen Stock Gains — Alzheimer’s Drug Has Baggage
Episode 1089th June 2021 • The Stock Power Podcast • Money & Markets
00:00:00 00:08:23

Share Episode

Shownotes

In November 2020, biotech analysts could not get enough of one particular stock after the company got a big break from the Food and Drug Administration (FDA).

At the time, the FDA ruled it had enough evidence to support approval of Biogen Inc.’s (Nasdaq: BIIB) experimental Alzheimer’s drug.

On Monday, the government approved aducanumab, better known as Aduhelm.

The announcement sent Biogen’s stock through the roof. It jumped as much as 60% before cutting some of those gains.

However, the approval came with two huge caveats:

·      An outside panel of experts did not endorse the treatment. It said the data shown during drug trials were “unconvincing.”

·     Biogen executives said they were going to charge $56,000 per year for the new treatment — five times more than expectations.

In this episode of The Bull & The Bear, I examine the approval of this Alzheimer’s treatment and what it means for Biogen and the broader biotech industry. I also tell you whether Biogen’s stock is a buy or not after this big news.

Be sure to also subscribe to our YouTube channel for more videos like my weekly Marijuana Market Update.

Have something you want us to talk about? Email thebullandthebear@moneyandmarkets.com and give us your thoughts.

Check out moneyandmarkets.com, and sign up for our free newsletters that deliver you the most important and unbiased financial news, commentary, and actionable advice.

Also, follow us on:

Facebook

Twitter

LinkedIn

Chapters